

In re LADNER, Robert C. et al (based on PCT/US92/01501)

A or B according to Table 65.

18. A homologous inhibitor of a reference inhibitor according to claim 2, said homologous inhibitor differing from said reference inhibitor by one or more substitutions of class A or B according to Table 65.

19. A homologous inhibitor of a reference inhibitor according to claim 3, said homologous inhibitor differing from said reference inhibitor by one or more substitutions of class A or B according to Table 65.

A²
20. A homologous inhibitor of a reference inhibitor according to claim 1, said homologous inhibitor differing from said reference inhibitor by one or more substitutions of class A, B or C according to Table 65.

21. A homologous inhibitor of a reference inhibitor according to claim 2, said homologous inhibitor differing from said reference inhibitor by one or more substitutions of class A, B or C according to Table 65.

22. A homologous inhibitor of a reference inhibitor according to claim 3, said homologous inhibitor differing from said reference inhibitor by one or more substitutions of class A, B or C according to Table 65.

23. A method for the treatment or prophylaxis of a condition of the body caused by excessive neutrophil elastase activity which comprises administering to a subject a neutrophil elastase activity-inhibiting amount of the inhibitor of claim 1, or of a homologous inhibitor differing from the inhibitor of claim 1 by one or more substitutions of

In re LADNER, Robert C. et al (based on PCT/US92/01501)

classes A, B or C according to Table 65.

24. A method for the treatment or prophylaxis of a condition of the body caused by excessive neutrophil elastase activity which comprises administering to a subject a neutrophil elastase activity-inhibiting amount of the inhibitor of claim 3, or of a homologous inhibitor differing from the inhibitor of claim 3 by one or more substitutions of classes A, B or C according to Table 65.

25. A method for the treatment or prophylaxis of a condition of the body caused by excessive neutrophil elastase activity which comprises administering to a subject a neutrophil elastase activity-inhibiting amount of the inhibitor of claim 7.

A²
26. A method for the treatment or prophylaxis of a condition of the body caused by excessive neutrophil elastase activity which comprises administering to a subject a neutrophil elastase activity-inhibiting amount of the inhibitor of claim 8.

27. A method for the treatment or prophylaxis of a condition of the body caused by excessive neutrophil elastase activity which comprises administering to a subject a neutrophil elastase activity-inhibiting amount of the inhibitor of claim 11.

28. A method for the treatment or prophylaxis of a condition of the body caused by excessive cathepsin G activity which comprises administering to a subject a cathepsin G activity-inhibiting amount of the inhibitor of claim 1, or of a homologous inhibitor differing from the